Want to see IT:PHN full AI Analyst Report?
PHN Stock Chart & Stats
€81.70
-€0.80(-1.51%)
At close: 4:00 PM EST
€81.70
-€0.80(-1.51%)
Day’s Range― - ―
52-Week Range€38.75 - €95.90
Previous CloseN/A
Volume2.81K
Average Volume (3M)25.97K
Market Cap
€849.02M
Enterprise Value€853.96M
Total Cash (Recent Filing)€29.00M
Total Debt (Recent Filing)€19.10M
Price to Earnings (P/E)39.5
Beta0.38
Next Earnings
Sep 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.86%
Share Statistics
EPS (TTM)2.22
Shares Outstanding9,680,977
10 Day Avg. Volume12,507
30 Day Avg. Volume25,966
Financial Highlights & Ratios
PEG Ratio1.25
Price to Book (P/B)7.28
Price to Sales (P/S)3.95
P/FCF Ratio31.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€95.50Price Target Upside16.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)2.54
Revenue Forecast (FY)€151.87M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationConsistent operating cash flow (~€19–21M) and positive free cash flow (~€16M) provide durable internal funding for capex, R&D, dividends or acquisitions. This cash generation underpins financial flexibility and reduces reliance on external financing over the medium term.
Improving Balance Sheet And Low LeverageMaterial reduction in debt and a low debt-to-equity (~0.29) with steadily built equity (~€75M) strengthen solvency and credit flexibility. This durable improvement supports strategic investment, cushions earnings shocks, and preserves optionality for long-term growth initiatives.
Sustained Revenue Growth With Healthy Net MarginsMulti-year top-line expansion and a stable ~15% net margin reflect durable demand for branded nutraceuticals and B2B contract activities. Consistent revenue scaling and margin retention support long-term cash flow potential and capacity to reinvest in proprietary formulations and geographic expansion.
Bears Say
Sharp Operating-profit DeteriorationA recent swing to negative operating profit and EBITDA margin materially weakens core earnings quality. If persistent, this undermines operating leverage, erodes the ability to fund growth from operations, and risks reversing prior strong returns on equity and cash-generation metrics.
Volatile Gross MarginsFluctuating gross margins suggest sensitivity to input costs, pricing power limits, or mix shifts between higher- and lower-margin products. This volatility makes long-term margin forecasting difficult and increases execution risk for sustaining profitability during cost or competitive pressure.
Free Cash Flow Volatility And Weak ConversionFCF below net income and historical swings (including negative years) indicate working-capital or capex timing risks. Irregular cash conversion can constrain consistent dividend payments, deleveraging, or reinvestment plans, reducing resilience if operating performance weakens.
PharmaNutra SpA News
PHN FAQ
What was PharmaNutra SpA’s price range in the past 12 months?
PharmaNutra SpA lowest stock price was €38.75 and its highest was €95.90 in the past 12 months.
What is PharmaNutra SpA’s market cap?
PharmaNutra SpA’s market cap is €849.02M.
When is PharmaNutra SpA’s upcoming earnings report date?
PharmaNutra SpA’s upcoming earnings report date is Sep 11, 2026 which is in 71 days.
How were PharmaNutra SpA’s earnings last quarter?
PharmaNutra SpA released its earnings results on May 11, 2026. The company reported €0.36 earnings per share for the quarter, beating the consensus estimate of N/A by €0.36.
Is PharmaNutra SpA overvalued?
According to Wall Street analysts PharmaNutra SpA’s price is currently Undervalued.
Does PharmaNutra SpA pay dividends?
PharmaNutra SpA pays a Annually dividend of €1.2 which represents an annual dividend yield of 1.86%. See more information on PharmaNutra SpA dividends here
What is PharmaNutra SpA’s EPS estimate?
PharmaNutra SpA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaNutra SpA have?
PharmaNutra SpA has 9,680,977 shares outstanding.
What happened to PharmaNutra SpA’s price movement after its last earnings report?
PharmaNutra SpA reported an EPS of €0.36 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.258%.
Which hedge fund is a major shareholder of PharmaNutra SpA?
Currently, no hedge funds are holding shares in IT:PHN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaNutra SpA
Pharmanutra S.p.A. functions as a pharmaceutical and nutraceutical enterprise, focusing on the research, development, design, and marketing of nutritional supplements and medical devices. Its market reach extends across Italy, other parts of Europe, the Middle East, the Far East, and globally. Moreover, the company manufactures and promotes pharmaceuticals, medical devices, over-the-counter (OTC) items, and nutraceuticals specifically for the pediatric population. Furthermore, Pharmanutra is a producer and supplier of raw materials and active ingredients to the food, pharmaceutical, and dietary supplement industries. Its diverse product portfolio features prominent brands like the SiderAL series (including SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med), the Cetilar range (Cetilar Crema, Cetilar Patch, Tape), along with ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. These products are distributed and sold through a network comprising sales representatives, wholesalers, pharmacies, and para-pharmacies. Established in 2003, the company's base of operations is in Pisa, Italy.
PHN Stock 12 Month Forecast
Average Price Target
€95.50
▲(16.89% Upside)
Technical Analysis
Garofalo Health Care S.P.A.
―
Arterra Bioscience SpA
―
Eukedos S.p.A.
―
Farmacosmo S.P.A.
―
Svas Biosana S.p.A.
―
Options Prices
Currently, No data available
---